Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

NCT07199855 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Acute Lymphoblastic Leukemia, Adult

Interventions

DRUG: blinatumomab combined with venetoclax as maintenance therapy

Sponsor

Zhejiang University